NCT04073017View on ClinicalTrials.gov

Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency

NATerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 4, 2019

Primary Completion Date

May 18, 2021

Study Completion Date

May 18, 2021

Conditions
Neuroendocrine TumorCarcinoid Syndrome
Interventions
DIETARY_SUPPLEMENT

Enterade®

Participants will drink an 8 ounce bottle of Enterade® twice a day for 4 weeks

OTHER

Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)

Ancillary studies

Trial Locations (1)

37232

Vanderbilt-Ingram Cancer Center, Nashville

Sponsors

Collaborators (1)

Entrinsic Bioscience Inc.
All Listed Sponsors
collaborator

Entrinsic Bioscience Inc.

INDUSTRY

lead

Vanderbilt-Ingram Cancer Center

OTHER